Therapeutic agent for urinary tract disease

A technology for urinary incontinence and urination disorder, which is applied in the field of therapeutic drugs for urinary system diseases, and can solve problems such as non-existence

Inactive Publication Date: 2009-10-14
ASKA PHARMACEUTICAL CO LTD
View PDF3 Cites 13 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] However, there is no literature addressing the correlation of PDE9 inhibition with therapeutic effects on urological disorders

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Therapeutic agent for urinary tract disease
  • Therapeutic agent for urinary tract disease
  • Therapeutic agent for urinary tract disease

Examples

Experimental program
Comparison scheme
Effect test

preparation example 1

[0498] 5-Methyl-4-oxo-2-(thiophen-3-ylmethyl)-3,4-dihydrothieno[2,3-d]pyrimidine-6-carba acid (Compound number: A-1)

[0499]

[0500] 1-a): 5-methyl-4-oxo-2-(thiophen-3-ylmethyl)-3,4-dihydrothieno[2,3-d]pyrimidine -Synthesis of ethyl 6-formate

[0501] Add 515 mg of 5-amino-3-methylthiophene-2,4-dicarboxylated diethyl ester and 296 mg of 3-thiopheneacetonitrile to 8 mL of 4N hydrogen chloride in dioxane, and stir for 10 hours. After stirring, the reaction mixture was placed on ice and adjusted to pH 8-9 with 25% ammonia water. The precipitated crystals were collected by filtration, washed with water and hexane in sequence. The crude crystals were recrystallized from a mixture of N,N-dimethylformamide and cyclohexane to obtain 397 mg of the title compound.

[0502] 1 H-NMR (DMSO-d 6 )δ: 1.30 (3H, t, J = 7.1Hz), 2.81 (3H, s), 3.97 (2H, s), 4.30 (2H, q, J = 7.1Hz), 7.0-7.6 (3H, m), 12.74 (1H, br s)

[0503] MS (m / z): 334 (M + )

[0504] 1-b): 5-methyl-4-oxo-...

preparation example 2

[0510] 5-Methyl-4-oxo-2-(thiophen-2-ylmethyl)-3,4-dihydrothieno[2,3-d]pyrimidine-6-carba acid (Compound number: A-2)

[0511]

[0512] 1 H-NMR (DMSO-d 6 )δ: 2.79 (3H, s), 4.17 (2H, s), 6.9-7.5 (3H, m), 12.75 (1H, br s), 13.35 (1H, br s)

[0513] MS (m / z): 306 (M + )

preparation example 3

[0515] 2-(5-Chlorothiophen-2-ylmethyl)-5-methyl-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidine -6-Formic acid (Compound number: A-3)

[0516]

[0517] 1 H-NMR (DMSO-d 6 )δ: 2.79 (3H, s), 4.13 (2H, s), 6.91 (1H, d, J = 3.9Hz), 6.98 (1H, d, J = 3.9Hz), 12.74 (1H, br s), 13.37 (1H, br s)

[0518] MS (m / z): 342 (M + +2), 340(M + )

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Disclosed is a therapeutic agent for difficulty in urination associated with overactive bladder, frequent urination, urinary incontinence or prostatomegaly or urinary calculus, which comprises a compound having a PDE9-inhibiting activity as an active ingredient.

Description

technical field [0001] The present invention relates to a therapeutic drug for overactive bladder, frequent urination, urinary incontinence, dysuria associated with prostatic hypertrophy, or urinary calculi, which is characterized in that it contains a compound having a phosphodiesterase type 9 (PDE9) inhibitory effect as an active ingredient . Background technique [0002] Urinary disorders are broadly classified into voiding disorders in which urine cannot be excreted with sufficient force during urination, and storage disorders in which urine cannot be preserved during the storage period. At present, alpha is mostly used in the treatment of discharge disorders 1 Blockers, and anticholinergic drugs are mostly used in the treatment of urinary storage disorders. However, the long-term therapeutic effect of these drugs is not sufficient, and there are disadvantages such as a decrease in the quality of life (QOL) due to side effects, so it is required to develop a new mechan...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61K31/4985A61K31/519A61P13/00A61P13/02A61P13/04A61P43/00C07D487/04C07D495/04
CPCC07D495/04A61K31/519C07D487/04A61K31/4985A61P13/00A61P13/02A61P13/04A61P13/10A61P43/00A61K31/517
Inventor 五反田浩太郎新保淳中野洋一小林秀男冈田亮朝乌章
Owner ASKA PHARMACEUTICAL CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap